NEW STORY CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
(World News Science)

CEL-SCI REACHES FULL ENROLLMENT IN PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY Major Milestone Achieved in World`s Largest Head and Neck Cancer Phase 3 Study Vienna, VA, December 11, 2017 -- CEL-SCI Corporation (NYSE American: CVM) announced today that no further patient enrollment is required in the pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). The accrual and treatment phases of this Phase 3 study are complete. All of the 928 enrolled patients in the study are being followed-up as required by the study protocol. CEL-SCI recently announced that the study`s Independent Data Monitoring Committee (IDMC) completed...